Medigene enters Cooperative Research and Development Agreement with the National Cancer Institute to evaluate the use of Medigene’s proprietary T cell receptors in novel cell constructs
Tuesday, April 04, 2023
Medigene AG, an early stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, and the National Cancer Institute (NCI) will collaborate to evaluate the potential of Medigene’s proprietary T cell receptors (TCRs) to be used in new cell constructs for the treatment of solid tumors. NCI is part of the National Institutes of Health.
“We are very pleased to begin this joint collaboration with the Laboratory of Cellular and Molecular Biology of the Center for Cancer Research at the NCI, headed by Dr. Lawrence Samelson,” said Professor Dolores Schendel, Chief Scientific Officer at Medigene. “Dr. Samelson’s expertise in T cell signaling and T cell exhaustion is very important for understanding the deficits in immune responses directed against solid tumors and how they might be mitigated. Medigene shares this common interest in finding new pathways to best mobilize and maintain critical functions of specialized killer cells to fight cancer. Through this collaboration we will expand the range of tools and technologies in our end-to-end technology platform and expect that this could lead to multiple immune cell types contributing to antitumor immune activity.”
Source: globenewswire.com
